DIA Biosimilars 2013

Quintiles

ICON names president of DOCS

Monday, October 17, 2011 10:59 AM

ICON has named Colin Stanley president of DOCS, the company’s global resourcing division. Stanley succeeds Mr. Bill Taaffe as president following his retirement earlier this year.

More... »

Cenduit: Now with Patient Reminders

Quintiles opens European headquarters in UK

Wednesday, October 12, 2011 10:42 AM

Quintiles has officially opened its new European headquarters in Reading, United Kingdom, bringing together employees from each of its four disciplines.

More... »

CRF Health – eCOA Forum

Quintiles names global head of clinical & data operations

Tuesday, October 11, 2011 10:59 AM

Quintiles has named Steven Skolsky global head of its clinical & data operations (CDO) unit, the core of the company’s clinical development division that monitors the clinical conduct at research sites and collects and manages data from thousands of patients in hundreds of clinical trials conducted around the world.

More... »

Survey: Mid-tier CROs shut out of post-marketing

Monday, October 3, 2011 08:02 AM

Large CROs garner 57% of the post-marketing studies currently being outsourced, while another 25% of that work is awarded to the few firms that specialize in safety. The remaining 19%? That’s scattered among numerous mid-sized CROs.

More... »

New technology earns Quintiles top 5 ranking

Monday, October 3, 2011 08:00 AM

Many companies brag about bringing innovative technology to the clinical trials industry. Quintiles doesn’t have to brag. The most recent InformationWeek 500 is doing that for it.

More... »

PPD names CEO, puts acquisition rumors in question

Monday, September 26, 2011 08:02 AM

PPD has named a new CEO, a move that strikes some in the industry as a little strange in the face of rumors that the publicly traded CRO is close to selling itself to a private equity firm.

More... »

Eisai partners with SFJ in new outsourcing model

Friday, September 9, 2011 11:30 AM

Eisai has put the late-stage clinical development, as well as the associated funding, of a candidate compound for thyroid cancer in the hands of SFJ Pharma, wholly subsidiary of a US-based company that specializes in getting innovative drugs to market in Japan, according to PharmaTimes.

More... »

PPD rumored to be in exclusive acquisition talks with D.C.-based private equity firm the Carlyle Group

Monday, August 22, 2011 08:02 AM

While many in the upper echelon of private equity investors have been courting CRO PPD, for now all but one have been shooed away: Washington, D.C.-based Carlyle Group.

More... »

PPD denies CRO merger rumors, but stays mum on possibility of private equity takeover

Monday, July 25, 2011 08:00 AM

In the wake of last week’s Wall Street Journal report claiming PPD might be putting itself on the block, the top-tier CRO responded with a statement that it is not discussing mergers with other CROs. But what about private equity firms?

More... »

PPD shares rise on takeover rumors

Monday, July 18, 2011 01:51 PM

Shares of CRO Pharmaceutical Product Development (PPD) rose 16% to levels not touched in more than two-and-a-half years on Monday, a day after a Wall Street Journal report said the company was looking to sell itself, reported Reuters.

More... »

CenterWatch Drugs in Clinical Trials Database Library. Drug intelligence right at your fingertips.
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs